Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alnylam Pharmaceuticals
Biotech
Roche, Alnylam celebrate second ph. 2 win for blood pressure med
In further proof that Roche’s $310 million bet will pay off, the Big Pharma’s Alnylam-partnered hypertension drug has notched another win.
James Waldron
Mar 5, 2024 9:05am
Agios' next-up PK med quelled transfusion need in some patients
Nov 20, 2023 11:24am
Roche's bet pays off as Alnylam hypertension med hits in phase 2
Sep 7, 2023 8:55am
BridgeBio lifts the hood on phase 3 acoramidis data
Aug 28, 2023 11:21am
Agios pays $17.5M for Alnylam's siRNA blood disease program
Aug 3, 2023 8:40am
Alnylam's RNAi approach to Alzheimer's reaches biomarker target
Jul 17, 2023 2:21am